The Current Ratio as of December 2024 (TTM) for Protalix BioTherapeutics, Inc. (PLX) is 1.98

According to Protalix BioTherapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 1.98. This represents a change of 27.03% compared to the average of 1.56 of the last 4 quarters.

Protalix BioTherapeutics, Inc. (PLX) Historical Current Ratio (quarterly & annually)

How has PLX Current Ratio performed in the past?

The mean historical Current Ratio of Protalix BioTherapeutics, Inc. over the last ten years is 2.23. The current 1.98 Current Ratio has changed 8.76% with respect to the historical average. Over the past ten years (40 quarters), PLX's Current Ratio was at its highest in in the March 2016 quarter at 8.22. The Current Ratio was at its lowest in in the December 2020 quarter at 0.64.

Protalix BioTherapeutics, Inc. (PLX) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Protalix BioTherapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Protalix BioTherapeutics, Inc. (PLX) Average Current Ratio

How has PLX Current Ratio performed in the past?

The current Current Ratio of Protalix BioTherapeutics, Inc. (PLX) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages

Protalix BioTherapeutics, Inc. (PLX) Current Ratio vs. Peers

How is PLX’s Current Ratio compared to its peers?

Protalix BioTherapeutics, Inc.’s Current Ratio is greater than Corvus Pharmaceuticals, Inc. (0.92), less than Aldeyra Therapeutics, Inc. (6.80), greater than Gamida Cell Ltd. (0.35), greater than Checkpoint Therapeutics, Inc. (0.29), less than Cidara Therapeutics, Inc. (3.54), greater than Akebia Therapeutics, Inc. (1.52), less than X4 Pharmaceuticals, Inc. (4.89), greater than Seres Therapeutics, Inc. (1.12), greater than eFFECTOR Therapeutics, Inc. (1.03), less than PDS Biotechnology Corporation (2.84), less than aTyr Pharma, Inc. (6.07), less than Elevation Oncology, Inc. (17.77), less than Lexicon Pharmaceuticals, Inc. (0), less than Iovance Biotherapeutics, Inc. (7.45), less than ImmunoGen, Inc. (4.22), less than null (5.47),

Build a custom stock screener for Protalix BioTherapeutics, Inc. (PLX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Protalix BioTherapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Protalix BioTherapeutics, Inc. (PLX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Protalix BioTherapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.